The members of the Austrian Preterm Outcome Study Group are provided in Appendix [1](#apa14767-app-0001){ref-type="app"}.

CLD

:   Chronic lung disease

GA

:   Gestational age

IVH

:   Intraventricular haemorrhage

NEC

:   Necrotising enterocolitis

ROP

:   Retinopathy of prematurity

SGA

:   Small for gestational age

Key notesThis study determined survival, short‐term morbidities and predictors for adverse outcome of very preterm infants in Austria.Overall survival rate of all live‐born infants included in the Network was high at 91.6% and prevalence of short‐term morbidities was low.Low gestational age, low birth weight, missing or incomplete course of antenatal steroids, male sex and multiple births were significant risk predictors for death or adverse short‐term outcome.

Introduction {#apa14767-sec-0006}
============

Advances in perinatal and neonatal care have gradually improved survival of very preterm infants. However, disability rates remain significant, especially among the most immature babies [1](#apa14767-bib-0001){ref-type="ref"}, [2](#apa14767-bib-0002){ref-type="ref"}. Since countries vary substantially in healthcare systems, in provision of proactive care for extremely preterm babies and available resources, national data are important for clinicians regarding decision‐making and objective counselling of parents.

So far, last data on mortality and morbidities of extremely preterm infants for Austria was published in 2005 and included infants born between 1999 and 2001 [3](#apa14767-bib-0003){ref-type="ref"}. Therefore, the Austrian Preterm Outcome Study Group was founded. The current national cohort study included all live‐born infants with a gestational age (GA) of 23 to 31 weeks born in Austria. There was only a very small number of infants with 22 weeks of gestation being treated in Austria.

Our aim was to report the rates of survival to discharge home and short‐term morbidities related to different GAs and to characterise risk predictors for death or adverse short‐term outcome in this national cohort.

Methods {#apa14767-sec-0007}
=======

The Austrian Preterm Outcome Study was based on data collected prospectively by the Austrian Preterm Outcome Study Network. The Network was established with the aim of reporting on survival and outcome in all live‐born very preterm infants born in this geographical region.

The Network comprises seven Level III (highest level) and 15 Level II (specialised for neonatal care) centres. All collaborators are listed at the end of the paper. In each centre, one neonatal study coordinator was responsible for data acquisition and quality control. Data were collected electronically with a secure interface that protected confidentiality and privacy of data.

For the current study, infants were included that were born alive with a GA between 23 + 0 and 31 + 6 weeks between 1 January 2011 and 31 December 2016 in Austria. Live birth was defined according to World Health Organization guidelines and refers 'to the complete expulsion or extraction from its mother of a product of conception, irrespective of the duration of the pregnancy, which, after such separation, breathes or shows any other evidence of life\' [4](#apa14767-bib-0004){ref-type="ref"}.

Ethics {#apa14767-sec-0008}
------

The Austrian Preterm Outcome Registry is part of a governmental quality assessment programme for neonatal care in Austria. Assessment of outcome until school entry for all preterm infants with a GA less than 32 weeks is mandatory and based on the federal law promoting quality in health care. Anonymised data are centrally administered by Gesundheit Österreich GmbH, and scientific analyses are approved and supervised by an academic review board.

Neonatal data {#apa14767-sec-0009}
-------------

GA was calculated from the first day of the last menstrual period. This was compared with assessment of GA by ultrasound scans performed before 24 weeks. A full course of antenatal steroids was considered as two doses with a 24 h interval, with the last dose administered more than 24 hours before birth. Small for gestational age (SGA) was defined as a birth weight less than the 10th percentile for GA [5](#apa14767-bib-0005){ref-type="ref"}.

Mortality {#apa14767-sec-0010}
---------

Overall mortality was defined as all deaths occurring after birth until discharge from hospital and included delivery room deaths and deaths on the neonatal intensive care unit.

Short‐term outcome {#apa14767-sec-0011}
------------------

The following major short‐term morbidities were analysed: chronic lung disease (CLD) defined as oxygen dependence at 36 weeks postconceptional age, necrotising enterocolitis (NEC) defined according to Bell\'s criteria [6](#apa14767-bib-0006){ref-type="ref"} and classified as medical by clinical symptoms and signs plus evidence of pneumatosis on abdominal x ray or defined as surgical NEC by histological evidence of NEC on surgical specimens of intestine, intraventricular haemorrhage (IVH) classified according to the method of Papile et al. [7](#apa14767-bib-0007){ref-type="ref"}, and retinopathy of prematurity (ROP) graded according to the international classification [8](#apa14767-bib-0008){ref-type="ref"}.

Adverse short‐time outcome {#apa14767-sec-0012}
--------------------------

Adverse short‐time outcome was defined as development of any of the following diseases: CLD, severe NEC (requiring surgical treatment), severe IVH (Grades 3--4), or severe ROP (Grades 3--5).

Survival free of major complications {#apa14767-sec-0013}
------------------------------------

Survival free of major complications was defined as percentage of the cohort surviving without one of the four major short‐term morbidities contributing to an adverse short‐time outcome.

Statistical analysis {#apa14767-sec-0014}
--------------------

Data analysis were performed using SPSS software, version 24.0 for Windows (IBM; Armonk, New York, USA). Descriptive statistics are provided in percentages, if not otherwise stated. Survival rates are presented as percentages with 95% binomial confidence intervals. Odds ratios and 95% confidence intervals for risk profiles for adverse short‐term outcome were calculated by logistic regression analysis. Parameters entered in the multivariate regression model were GA, birth weight, antenatal steroids, sex and multiple births. p \< 0.05 was considered statistically significant. To account for clustering of multiple births odds ratios and 95% confidence intervals were also calculated by a generalised linear model which was extended by generalised estimating equations. Parameters entered in this model were GA, birth weight, antenatal steroids and sex. p \< 0.05 was considered statistically significant.

Results {#apa14767-sec-0015}
=======

Over the six‐year period, there were 5843 live‐born infants with a GA between 23 + 0 and 31 + 6 weeks in Austria (data from the National Birth Registry). Data on 5197 live‐born infants (89%) were entered into the registry and hence included in our analysis. In more detail, data were 95% complete for the GA range between 24 and 29 weeks of gestation, and missing data were more common for infants at the border of viability, namely a GA of 23 weeks (73% participation rate) and for infants with a GA of 30 and 31 weeks (participation rates of 84% and 74%), who were less likely admitted to one of the 22 participating centres.

Neonatal characteristics of infants born alive during the study period were summarised by year and by GA and are shown in Table [1](#apa14767-tbl-0001){ref-type="table"}a and b. There were no significant differences in use of antenatal corticosteroids, mode of birth, or infants born SGA over the six‐year period. There was a significant decrease in number of multiple births during the study period (p = 0.045; Table [1](#apa14767-tbl-0001){ref-type="table"}a). The most immature babies with a GA of 23 weeks had a low rate of lung maturation with only 38.5% having received a completed course of antenatal steroids. The rates of mortality and short‐term morbidities decreased with increasing GA (Table [1](#apa14767-tbl-0001){ref-type="table"}b).

###### 

Sociodemographic and neonatal characteristics of preterm infants \<32 weeks gestational age (a) by year, (b) gestational age

  \(a\)                                                                                                                     
  ----------------------------------------- -------------- ------------ ------------ ------------ ------------ ------------ ------------
  Live births                               5197 (100.0)   877 (16.9)   853 (16.4)   865 (16.6)   914 (17.6)   821 (15.6)   867 (16.7)
  Male sex                                  2769 (53.3)    463 (52.8)   456 (53.5)   465 (53.8)   489 (53.5)   441 (53.7)   455 (52.5)
  Mortality                                 436 (8.4)      65 (7.4)     72 (8.4)     64 (7.4)     55 (6.0)     113 (13.8)   67 (7.7)
  SGA                                       667 (12.8)     111 (12.7)   110 (12.9)   123 (14.2)   117 (12.8)   100 (12.2)   106 (12.2)
  Multiple births                           1677 (32.3)    311 (35.5)   266 (31.2)   309 (35.7)   282 (30.9)   248 (30.2)   261 (30.1)
  Caesarean section                         4321 (83.1)    735 (83.8)   711 (83.4)   732 (84.6)   752 (82.3)   674 (82.2)   717 (82.7)
  Antenatal steroids -- incomplete course   1056 (20.3)    180 (20.5)   168 (19.7)   216 (25.0)   180 (19.7)   140 (17.1)   172 (19.8)
  Antenatal steroids -- complete course     3346 (64.4)    563 (64.2)   539 (63.2)   541 (62.5)   595 (65.1)   524 (66.0)   566 (65.3)
  IVH (all)                                 906 (17.4)     190 (21.7)   158 (18.5)   142 (16.4)   150 (16.4)   130 (15.8)   136 (15.7)
  Severe IVH (Grades 3--4)                  285 (5.5)      60 (6.8)     57 (6.7)     40 (4.6)     38 (4.2)     43 (5.2)     47 (5.4)
  NEC                                       208 (4.0)      31 (3.5)     30 (3.5)     34 (3.9)     35 (3.8)     36 (4.4)     42 (4.8)
  Severe NEC                                111 (2.1)      14 (1.6)     14 (1.6)     17 (2.0)     20 (2.2)     22 (2.7)     24 (2.8)
  CLD                                       518 (10.0)     93 (10.6)    82 (9.6)     99 (11.4)    96 (10.5)    67 (8.2)     81 (9.3)
  ROP (all)                                 999 (19.2)     156 (17.8)   148 (17.4)   170 (19.7)   174 (19.0)   167 (20.3)   184 (21.2)
  Severe ROP (Grades 3--5)                  187 (3.6)      45 (5.1)     36 (4.2)     38 (4.4)     28 (3.1)     10 (1.2)     30 (3.5)

  \(b\)                                                                                                                                                                                        
  ----------------------------------------- -------------- ------------- ------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ -------------
  Live births                               5197 (100.0)   1771 (34.1)   3426 (65.9)   187 (3.6)    297 (5.7)    331 (6.4)    422 (8.1)    534 (10.3)   662 (12.7)   757 (14.6)   941 (18.1)   1066 (20.5)
  Male sex                                  2769 (53.3)    966 (54.5)    1803 (52.6)   104 (55.6)   156 (52.5)   180 (54.4)   232 (55.0)   294 (55.1)   361 (54.5)   393 (51.9)   497 (52.8)   552 (51.8)
  Mortality                                 436 (8.4)      316 (17.8)    120 (3.5)     99 (52.9)    79 (26.6)    50 (15.1)    50 (11.8)    38 (7.1)     22 (3.3)     24 (3.2)     38 (4.0)     36 (3.4)
  SGA                                       667 (12.8)     224 (12.6)    443 (12.9)    23 (12.3)    33 (11.1)    38 (11.5)    59 (14.0)    71 (13.3)    91 (13.7)    94 (12.4)    123 (13.1)   135 (12.7)
  Multiple births                           1677 (32.3)    465 (26.3)    1212 (35.4)   56 (29.9)    66 (22.2)    98 (29.6)    102 (24.2)   143 (26.8)   215 (32.5)   252 (33.3)   324 (34.4)   421 (39.5)
  Caesarean section                         4321 (83.1)    1404 (79.3)   2917 (85.1)   87 (46.5)    232 (78.1)   281 (84.9)   360 (85.3)   444 (83.1)   571 (86.3)   654 (86.4)   800 (85.0)   892 (83.7)
  Antenatal steroids -- incomplete course   1056 (20.3)    381 (21.5)    675 (19.7)    61 (32.6)    70 (23.6)    76 (23.0)    94 (22.3)    80 (15.0)    122 (18.4)   140 (18.5)   183 (19.4)   230 (21.6)
  Antenatal steroids -- complete course     3346 (64.4)    1103 (62.3)   2243 (65.5)   72 (38.5)    174 (58.6)   212 (64.0)   273 (64.7)   372 (69.7)   461 (69.6)   517 (68.3)   607 (64.5)   658 (61.7)
  IVH (all)                                 906 (17.4)     533 (30.1)    373 (10.9)    92 (49.2)    126 (42.4)   101 (30.5)   101 (23.9)   113 (21.2)   106 (16.0)   96 (12.7)    103 (10.9)   68 (6.4)
  Severe IVH(Grades 3--4)                   285 (5.5)      223 (12.6)    62 (1.8)      53 (28.3)    51 (17.2)    45 (13.6)    35 (8.3)     39 (7.3)     23 (3.5)     20 (2.6)     13 (1.4)     6 (0.6)
  NEC                                       208 (4.0)      137 (7.7)     71 (2.1)      22 (11.8)    31 (10.4)    24 (7.3)     43 (10.2)    17 (3.2)     21 (3.2)     18 (2.4)     23 (2.4)     9 (0.8)
  Severe NEC                                111 (2.1)      78 (4.4)      33 (1.0)      13 (7.0)     19 (6.4)     11 (3.3)     25 (5.9)     10 (1.9)     9 (1.4)      9 (1.2)      10 (1.1)     5 (0.5)
  CLD                                       518 (10.0)     409 (23.1)    109 (3.2)     51 (27.3)    103 (34.7)   108 (32.6)   75 (17.8)    72 (13.5)    54 (8.2)     31 (4.1)     15 (1.6)     9 (0.8)
  ROP (all)                                 999 (19.2)     737 (41.6)    262 (7.6)     69 (36.9)    165 (55.6)   187 (56.5)   158 (37.4)   158 (29.6)   107 (16.2)   78 (10.3)    54 (5.7)     23 (2.2)
  Severe ROP (Grades 3--5)                  187 (3.6)      165 (9.3)     22(0.6)       36 (19.3)    62 (20.9)    30 (9.1)     25 (5.9)     12 (2.2)     10 (1.5)     6 (0.8)      4 (0.4)      2 (0.2)

CLD, chronic lung disease; IVH, intraventricular haemorrhage; NEC, necrotising enterocolitis; ROP, retinopathy of prematurity; SGA, small for gestational age.

John Wiley & Sons, Ltd

Mortality {#apa14767-sec-0016}
---------

Of 5197 live‐born infants, 436 (8.4%) died during the study period (2011--2016). There was no significant decrease in mortality over this six‐year period. Death rates in infants having 23, 24, 25, 26, and 27 weeks of gestation were 52.9%, 26.6%, 15.1%, 11.8%, 7.1%, respectively. Corresponding death rates for infants having a GA of 28, 29, 30, and 31 weeks were 3.3%, 3.2%, 4.0% and 3.4%, respectively. There was no significant difference in death rate between males and females (9.2% vs. 7.6%, p = 0.07). Survival percentages and 95% confidence intervals by GA are shown in Figure [1](#apa14767-fig-0001){ref-type="fig"}.

![Survival to discharge plotted against gestational age.](APA-108-1419-g001){#apa14767-fig-0001}

Adverse short‐term outcome {#apa14767-sec-0017}
--------------------------

The overall prevalence of major morbidities was 10.0% for CLD, 2.1% for severe NEC, 5.5% for IVH Grades 3--4, and 3.6% for ROP Grades 3--5. Prevalence of adverse short‐term outcome ranged from 55.6% in infants with 23 weeks of gestation to 13.1% in those with 28 weeks and 1.9% in infants with 31 weeks of gestation (Table [2](#apa14767-tbl-0002){ref-type="table"}). There was no significant change in adverse short‐term outcome over the six‐year period (p = 0.531). The overall rate of death or adverse short‐term outcome was 21.8% ranging from 86.1% to 4.9% according to GA (Table [2](#apa14767-tbl-0002){ref-type="table"}).

###### 

Short‐term outcomes of preterm infants \<32 weeks gestational age 2011--2016

                                                    Total         Gestational age, weeks                                                                                                                         
  --------------------------------------- --------- ------------- ------------------------ ------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ -------------
  Adverse short‐term outcome              *N* (%)   860 (16.5)    654 (36.9)               206 (6.0)     104 (55.6)   168 (56.6)   150 (45.3)   121 (28.7)   111 (20.8)   87 (13.1)    59 (7.8)     40 (4.3)     20 (1.9)
  Death or adverse short‐term outcome     *N* (%)   1132 (21.8)   829 (46.8)               303 (8.8)     161 (86.1)   208 (70.0)   175 (52.9)   153 (36.3)   132 (24.7)   100 (15.1)   80 (10.6)    71 (7.5)     52 (4.9)
  Alive with adverse short‐term outcome   *N* (%)   696(13.4)     513 (29.0)               183 (5.3)     62 (33.2)    129 (43.4)   125 (37.8)   103 (24.4)   94 (17.6)    78 (11.8)    56 (7.4)     33 (3.5)     16 (1.5)
  Survival free of major complications    *N* (%)   4065 (78.2)   942 (53.2)               3123 (91.2)   26 (13.9)    89 (30.0)    156 (47.1)   269 (63.7)   402 (75.3)   562 (84.9)   677 (89.4)   870 (92.5)   1014 (95.1)

Adverse short‐time outcome (CLD, severe NEC, severe IVH, or severe ROP); survival free of major complications (survival without CLD, severe NEC, severe IVH, or severe ROP).

John Wiley & Sons, Ltd

In a multivariate approach low GA, low birth weight, missing or incomplete course of antenatal steroids, male sex and multiple births were significant risk predictors for death or adverse short‐term outcome (Table [3](#apa14767-tbl-0003){ref-type="table"}). When using the generalised linear model to account for clustering of multiple births results were almost identical to those obtained by logistic regression analysis.

###### 

Multivariate association between risk variables and death or adverse short‐term outcome (severe IVH ≥3, severe NEC, ROP ≥3, or CLD) in preterm infants \<32 weeks gestational age 2011--2016

  Variable                                                           Univariate          Multivariate                       
  ------------------------------------------------------------------ ------------------- -------------- ------------------- ---------
  Low gestational age (one‐week decrement)                           1.76 (1.70--1.83)   \<0.001        1.49 (1.40--1.56)   \<0.001
  Low birth weight (100 g decrement)                                 1.43 (1.39--1.47)   \<0.001        1.16 (1.12--1.21)   \<0.001
  Antenatal corticosteroids (no or incomplete vs. complete course)   1.62 (1.40--1.86)   \<0.001        1.60 (1.35--1.89)   \<0.001
  Male sex (vs. female)                                              1.34 (1.17--1.53)   \<0.001        1.50 (1.27--1.77)   \<0.001
  Multiple births                                                    1.49 (1.30--1.73)   \<0.001        1.22 (1.02--1.46)   0.029

CI, confidence interval; OR, odds ratio derived from logistic regression analysis of risk variables for adverse short‐term outcome.

The multivariate model \[Chi‐square (5) = 1312.596; p \< 0.001; included in analysis *N* = 4888\] was fitted with a forward stepwise selection procedure.

John Wiley & Sons, Ltd

Survival free of major complications {#apa14767-sec-0018}
------------------------------------

Overall survival free of major short‐term morbidity was 78.2%. Rates of survival without adverse short‐time outcome by gestational weeks are shown in Table [2](#apa14767-tbl-0002){ref-type="table"} and ranged from 13.9% at 23 weeks to up to 95.1% at 31 weeks and did not significantly increase between 2011 and 2016.

Discussion {#apa14767-sec-0019}
==========

In this population‐based cohort of very preterm‐born infants studied between 2011 and 2016, the overall survival rate of live‐born infants was 91.6%. Survival rate in the extremely preterm age group (GA 23--27 weeks) was also high, starting at a 47.1% in infants with a GA of 23 weeks and rising steeply to 85% in infants with 25 weeks of gestation (Fig. [1](#apa14767-fig-0001){ref-type="fig"}). Compared to the data from Austria from 1999--2001 [3](#apa14767-bib-0003){ref-type="ref"} there was improvement in all aspects, now there is less mortality and less morbidity within the reported population. However, there was no further reduction in mortality and morbidity during the study period which might probably be due to a time interval of six years only. In a recent paper from Switzerland, Chen et al. reported on trends over a 13‐year period and compared three time periods [9](#apa14767-bib-0009){ref-type="ref"}. Survival and severe ICH showed a significant improvement only when the periods 2000--2004 and 2009--2012 were compared, NEC and CLD remained the same.

Available studies of the outcomes of preterm infants have reported varying data on survival, especially regarding the extremely preterm group [1](#apa14767-bib-0001){ref-type="ref"}, [10](#apa14767-bib-0010){ref-type="ref"}, [11](#apa14767-bib-0011){ref-type="ref"}, [12](#apa14767-bib-0012){ref-type="ref"}, [13](#apa14767-bib-0013){ref-type="ref"}, [14](#apa14767-bib-0014){ref-type="ref"}, [15](#apa14767-bib-0015){ref-type="ref"}, [16](#apa14767-bib-0016){ref-type="ref"}, [17](#apa14767-bib-0017){ref-type="ref"}, [18](#apa14767-bib-0018){ref-type="ref"}, ranging from 35% (18) to 70% (1), and from 59% (18) to 81% (1) for those at 25 weeks of gestation. Differences in care practices at the limit of viability [19](#apa14767-bib-0019){ref-type="ref"}, different study periods as well as different study cohorts (all births vs. all livebirths) may contribute to the variations in reported survival rates [20](#apa14767-bib-0020){ref-type="ref"}. Management of infants with 22 weeks of gestation is discussed controversially in literature, because survival to discharge is poor in many countries, nevertheless, there are some countries that showed improved survival for those infants [21](#apa14767-bib-0021){ref-type="ref"}. However, for babies born at 23 and 24 weeks weighing 500 g and above, survival for all births including stillbirth varies between 0% to 25% and 21% to 50% in five different European countries [22](#apa14767-bib-0022){ref-type="ref"}.

In our cohort, overall survival free of adverse short‐term outcome was 78.2% and overall prevalence of CLD, severe NEC, IVH Grades 3--4, and severe ROP was 10.0%, 2.1%, 5.5%, and 3.6%, respectively. In comparison to other studies, outcome results in the EPIPAGE‐2 (Etude Epidémiologique sur les Petits Ages Gestationnels 2) cohort [17](#apa14767-bib-0017){ref-type="ref"} were similar, namely 82.9% survival free of severe neonatal morbidities for those born between 23 and 31 weeks of gestation. In EPIPAGE‐2, prevalence of severe CLD, severe NEC, severe IVH, and severe ROP was 8.0%, 3.7%, 5.3% and 1.2%, respectively [17](#apa14767-bib-0017){ref-type="ref"}. Other studies including only extremely preterm infants reported much higher rates of short‐term morbidities [10](#apa14767-bib-0010){ref-type="ref"}, [13](#apa14767-bib-0013){ref-type="ref"}. CLD, one of the most frequent complications in extremely preterm babies, was reported with a prevalence ranging from 25% (1) to 44% (13), and the prevalence of severe ROP showed ranges from 8% (9) to 34% (1). The lowest prevalence of severe IVH in extremely preterm infants (6.0% and 6.9%) was reported in a Swedish [12](#apa14767-bib-0012){ref-type="ref"} and a Dutch [10](#apa14767-bib-0010){ref-type="ref"} study, respectively, as well as 5.3% reported in a study also including very preterm infants [17](#apa14767-bib-0017){ref-type="ref"}. The rate of NEC in high‐income countries was reported to range from 5% to 22% among babies with a birth weight \< 1000 g [23](#apa14767-bib-0023){ref-type="ref"}. A recent international comparison between seven countries (Australia and New Zealand, Canada, Israel, Japan, Spain, Sweden and Switzerland) of infants admitted to the neonatal intensive care unit without major congenital malformation and born weighing less than 1500 g at 24--31 weeks of gestation showed great variations in adverse short‐time outcome (26%--42%) as well as overall mortality rate (5%--17%) and in each morbidity across these countries; for example, the country with the lowest mortality had the highest rate of treatment for ROP, and the country with the greatest mortality had a relatively low rate of CLD [24](#apa14767-bib-0024){ref-type="ref"}. However, when comparing these data to data from our cohort, both an overall mortality rate also including babies born at 23 weeks of GA of 8.4% as well as a rate of death or adverse short‐term of 21.8% in our cohort were within the lower ranges.

When calculating risk predictors for death or adverse short‐term outcome, not only low GA and low birth weight, but also missing or incomplete course of antenatal steroids, male sex, and multiple births were significantly associated with adverse outcome. Our findings are in accordance with the study conducted by Tyson et al. who found that the likelihood of a favourable outcome in extremely premature infants is dependent not only on GA, but also on birth weight, multiple births, sex, and exposure to antenatal corticosteroids [25](#apa14767-bib-0025){ref-type="ref"}. Regarding multiple births and mortality risk results of various studies differ, with some reporting similar risk rates [26](#apa14767-bib-0026){ref-type="ref"}, others showing no difference [27](#apa14767-bib-0027){ref-type="ref"}, or even a reduced risk for multiples [28](#apa14767-bib-0028){ref-type="ref"}.

Further implications {#apa14767-sec-0020}
--------------------

Even if a GA‐related mortality rate of 47.1% and a rate of adverse short‐term outcome of 55.6% for infants born with 23 weeks GA is low in comparison to other cohorts [9](#apa14767-bib-0009){ref-type="ref"}, [17](#apa14767-bib-0017){ref-type="ref"}, improvement in the care of the most immature babies is mandatory to further decrease overall mortality and morbidity rates. In addition, the overall rate of completed course of antenatal steroids of 65.3% has to be increased. Regarding a prevalence of 38.5% for babies with a GA of 23 weeks this is particularly true for the most immature babies, but also applies to the more mature ones. Considering the fact that missing or incomplete course of antenatal steroids was significantly associated with an increased risk for death or adverse short‐term outcome in our cohort this is of outmost importance.

Strengths and limitations of this study {#apa14767-sec-0021}
---------------------------------------

A strength of the current study was the population‐based cohort design with a prospective enrolment of infants born very preterm. These outcomes have been reported infrequently, because most studies focus on extremely preterm infants only. Even though children born between 27 and 31 weeks of GA have a lower relative risk for adverse outcome, they make up a much larger proportion of preterm births and in absolute numbers they account for most children with deficits [29](#apa14767-bib-0029){ref-type="ref"}. This study gives the first description of short‐term outcome of very preterm infants born in Austria.

Our study had some limitations. Only 89% of all live‐born very preterm infants in the Austrian Preterm Birth Cohort were able to be included in the Austrian Preterm Outcome Registry. Considering the fact that data entry was based on voluntariness and no funding was available for individual centres, the inclusion rate seems adequate and is comparable to other studies: missing data in other population studies ranged from 3% in the Israel Neonatal Network to up to more than 40% in the Neonatal Research Network of Japan [24](#apa14767-bib-0024){ref-type="ref"}. However, more favourable outcomes might entail a selection bias, which is a well‐known limitation of population‐based studies. This is especially true for infants born at the border of viability. In addition, delivery room mortality could not be extracted from our mortality data. Therefore, live births where therapy was withheld in the further course were also included in our death rates. On the other hand, variation in the classification whether delivery room death was recorded as a stillbirth or as a live birth cannot be excluded and might also have an impact on the observed neonatal mortality rate. The EPIPAGE cohort study, a comparable population‐based study including all infants born before 33 weeks of GA, showed an overall difference in survival rates of 8% for the whole cohort and about 20% for the lower GA groups depending on whether all births or all live births were included [11](#apa14767-bib-0011){ref-type="ref"}. To further improve data quality of the Austrian Preterm Outcome Study Network all births including stillbirths will be documented in the database from 2019 onwards.

To compare our outcome data to those of other populations, the Austrian healthcare system and policy on treatment of very preterm infants must be taken into account. According to national guidelines, proactive care is offered to extremely preterm babies with a gestational age of 23 weeks or older [30](#apa14767-bib-0030){ref-type="ref"}. Prenatal care in Austria is well structured, free of charge and accessible for every pregnant woman. For uncomplicated pregnancies and term deliveries at least five well‐documented health check‐ups during pregnancy are necessary to qualify for financial benefit. Also perinatal and neonatal health care including intensive care is accessible without additional costs for every baby. This health system may lead to better care in pregnancy and in the neonatal period and might also be one explanation for the overall favourable outcome data.

Conclusion {#apa14767-sec-0022}
==========

Our population‐based study from Austria of very preterm infants showed mortality and also short‐term morbidity rates low in regard to literature. These national data provide additional information to help make appropriate recommendations in treatment and can help further improve outcome of very preterm babies.
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